Viewing Study NCT05959356


Ignite Creation Date: 2025-12-24 @ 11:37 PM
Ignite Modification Date: 2025-12-25 @ 9:27 PM
Study NCT ID: NCT05959356
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2023-07-16
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
Sponsor: Sun Yat-sen University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module